Ovid Therapeutics Inc
Statements
Cash Flow
Ovid Therapeutics Inc (OVID) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -18 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.6 | -5.7 | -7.2 | -6.0 | -9.3 | -9.0 | -13 | -12 | -10 | -11 | -13 | -12 | -9.5 | -17 | -18 | -17 | -1.5 | -15 | 161 | -19 | -11 | -12 | -20 | -13 | -13 | -9.2 | -12 | -12 | -10 | -12 | -17 | -14 | -15 | -10 | -10 | -4.8 | -13 | -10 | -14 | -18 | -55 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 1.1 | 1.0 | 1.4 | 2.2 | 1.4 | 1.4 | 1.8 | 1.8 | 1.7 | 1.7 | 1.6 | 1.3 | 1.2 | 1.1 | 1.3 | 1.6 | 2.6 | 2.1 | 1.3 | 1.3 | 1.2 | 1.3 | 1.3 | 1.7 | 1.8 | 1.7 | 1.9 | 1.9 | 1.6 | 1.8 | 2.0 | 1.7 | 1.3 | 1.3 | 1.3 | 1.2 | 1.1 | 1.2 | 1.0 | 1.4 | 4.8 | |
| – | 3.6 | 1.4 | 2.2 | 1.4 | 32 | 1.8 | 1.8 | 1.7 | 1.7 | 1.6 | 1.3 | 1.2 | 1.1 | 1.3 | 1.6 | 2.6 | 2.1 | 1.3 | 1.3 | 1.2 | 1.3 | 1.3 | 1.7 | 1.2 | 1.7 | 1.9 | 1.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.8 | -0.2 | 2.1 | -1.4 | 0.5 | -1.6 | -0.5 | 1.2 | 0.1 | -0.8 | -0.1 | 5.9 | -1.1 | 0.4 | 3.8 | 12 | 5.4 | -17 | -4.9 | -0.7 | 5.3 | -4.3 | -1.5 | -2.4 | -0.1 | -0.3 | -1.0 | 0.0 | 3.7 | -1.7 | 4.2 | -1.7 | -0.9 | -1.3 | -1.2 | -1.7 | 0.1 | 2.3 | -2.1 | -1.4 | |
| 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 1.3 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.1 | -0.1 | -0.1 | 0.0 | 0.0 | 0.1 | -45 | 4.9 | 18 | 17 | 0.0 | 5.0 | 0.0 | -35 | 3.8 | 31 | 0.0 | -0.1 | 0.0 | -1.6 | -0.1 | -0.2 | -1.1 | -81 | -2.0 | -4.2 | 30 | 20 | -4.4 | -49 | 20 | 13 | 0.3 | 21 | 5.1 | 12 | 5.1 | -72 | 6.0 | -87 | -148 | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 70 | 0.0 | 67 | -0.7 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 31 | -0.4 | 0.1 | 34 | 0.0 | 0.2 | 47 | -0.2 | 0.1 | 0.1 | 0.5 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 15,449 | – | -15,449 | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 0.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0 | -0.5 | 68 | -0.7 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 31 | -0.4 | 0.1 | 56 | 0.0 | 0.2 | 47 | -0.2 | 0.1 | 0.1 | 0.5 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.2 | 30 | 0.2 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 75 | 89 | 22 | 186 | |
| -4.7 | -5.8 | -7.7 | 62 | -10 | -8.9 | -58 | -6.7 | 8.0 | 6.0 | 18 | -7.2 | -9.5 | 4.0 | -15 | 14 | 46 | -15 | 161 | -21 | -10 | -14 | -21 | -94 | -15 | -13 | 18 | 8.6 | -14 | -30 | 3.7 | -1.1 | -15 | 11 | -5.2 | 7.3 | -7.8 | -7.5 | 81 | -83 | -17 | |
| -4.7 | -5.8 | -7.2 | -6.0 | -9.3 | -9.0 | -13 | -12 | -10 | -11 | -13 | -12 | -9.5 | -17 | -19 | -17 | -1.5 | -15 | 161 | -19 | -11 | -12 | -20 | -15 | -13 | -9.2 | -12 | -12 | -10 | -12 | -17 | -14 | -15 | -10 | -10 | -4.8 | -13 | -10 | -14 | -18 | -55 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.